Vir Advances HBV, Flu Programs While Focused On COVID-19
Company Brought In Significant Cash Before And After Its IPO
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.
